Holen Sie sich die Stockscreener-App
8.47
2.17%
0.18
Handel nachbörslich:
8.45
-0.02
-0.24%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
BCRX (NASDAQ) Form 144: Affiliate plans resale of 11,180 shares - Stock Titan
BioCryst’s SWOT analysis: rare disease stock eyes growth path By Investing.com - Investing.com Nigeria
BioCryst’s SWOT analysis: rare disease stock eyes growth path - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth beyond single product - Investing.com
BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability - Investing.com UK
BioCryst Pharmaceuticals’ SWOT analysis: stock aims for profitability By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path - Investing.com
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
Responsive Playbooks and the BCRX Inflection - Stock Traders Daily
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX) - Sahm
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Biocryst (BCRX) CLO sells 62,500 shares in pre-set 10b5-1 trade - Stock Titan
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case - Sahm
BioCryst Pharmaceuticals stock (US09058V1035): Shares surge 9% after earnings - AD HOC NEWS
BCRX Jumps As Price Target Hike Caps Busy Catalyst Week - StocksToTrade
62,500-share resale registered by BCRX insider (NASDAQ: BCRX) - Stock Titan
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 - The Manila Times
BioCryst Pharmaceuticals to Present New Research on Pediatric Hereditary Angioedema at ISPOR 2026 Conference - Quiver Quantitative
BioCryst to Present New Real-World Evidence Underscoring - GlobeNewswire
Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition - PR Newswire
Study: Kids with rare swelling disorder log 3x outpatient visits vs peers - Stock Titan
BioCryst Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BioCryst Q1 2026 slides: dual HAE strategy targets $1.8B revenue - Investing.com Canada
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up By Investing.com - Investing.com South Africa
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed? - Yahoo Finance
State Street (NASDAQ: BCRX) holds 4.9% of BioCryst, 12.2M shares - Stock Titan
Influenza Therapeutics Market to Reach USD 12.94 Billion by 2033 - openPR.com
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal - Yahoo Finance
European patients gain future access to HAE drug navenibart in $300M deal - Angioedema News
Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes - Sahm
Number of shareholders of BioCryst Pharmaceuticals, Inc. – FWB:BO1 - TradingView
These analysts revise their forecasts on BioCryst Pharma after Q1 earnings - MSN
BioCryst Pharmaceuticals (NASDAQ:BCRX) Rating Lowered to Hold at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
BioCryst (BCRX) Q1 2026 Earnings Transcript - AOL.com
BCRX Adjusts FY26 Revenue Outlook with Key Estimates - GuruFocus
BioCryst (BCRX) Reports Q1 Revenue Growth Amid Significant Loss - GuruFocus
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):